Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aldrick B. Verano has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Ana Mallo-Abreu

    Laboratory of Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Av. Joan XXIII 27-31, E-08028 Barcelona, Spain

    1 shared publication
  • Anna Sampietro

    Laboratory of Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Av. Joan XXIII 27-31, E-08028 Barcelona, Spain

    1 shared publication
  • Belén Pérez

    Department of Pharmacology, Therapeutics and Toxicology, Autonomous University of Barcelona, E-08193 Bellaterra, Spain

    1 shared publication
  • Carles Galdeano

    Departament de Farmacia i Tecnología Farmacèutica, i Fisicoquímica Institut de Biomedicina (IBUB), Universitat de Barcelona Av. Joan XXIII, 27‐31, E‐08028 Barcelona Spain

    1 shared publication
  • Diego Muñoz-Torrero

    Laboratory of Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain

    1 shared publication
  • Jordi Juárez-Jiménez

    Unitat de Fisicoquímica, Departament de Farmàcia i Tecnologia Farmacèutica, i Fisicoquímica, Facultat de Farmàcia i Ciències de l’Alimentació, Universitat de Barcelona (UB), Av. Joan XXIII, 27-31, 08028 Barcelona, Spain

    1 shared publication

Latest Publications

  • Open Access

    Synthesis and Biological Profiling of New 1,2,3,4-Tetrahydrobenzo[h]naphthyridine-Based Hybrids as Dual Inhibitors of β-Amyloid and Tau Aggregation with Anticholinesterase Activity

    by Aldrick B. Verano, Anna Sampietro, Ana Mallo-Abreu, Rosaria Spagnuolo, Belén Pérez, Manuela Bartolini, María Isabel Loza, José Brea, Jordi Juárez-Jiménez, Raimon Sabate, et al.

    DP-128 is a multitarget benzonaphthyridine-6-chlorotacrine hybrid molecule with potent in vitro anticholinesterase and Aβ42 and tau anti-aggregating activity. While often used as a reference protein aggregation inhibitor, its further development as an anti-Alzheimer agent is limited by significant cytotoxicity, suboptimal aqueous solubility and microsomal stability. Since these drawbacks might arise from its rather high lipophilicity, in this work we have developed a series of more polar analogues, designed by structural modifications at the benzonaphthyridine or 6-chlorotacrine moieties or within the eight-atom linker. Half of the new analogues are indeed slightly more soluble and clearly less cytotoxic than DP-128, display single-digit acetylcholinesterase inhibitory activity, and retain the Aβ42 and tau anti-aggregating potency of the lead, as well as favourable brain permeation and high plasma stability. While further optimization of microsomal stability is necessary for a potential therapeutic use of this class of compounds, hybrids 16 and 17, with similar or even higher Aβ42 and tau anti-aggregating activity and lower cytotoxicity than DP-128, might represent novel pharmacological tools for protein aggregation studies.